Phathom Pharmaceuticals, Inc. Capital expenditures

Capital expenditures of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital expenditures for the quarter ending June 29, 2021 was $-45 Thousand (a -73.37% decrease compared to previous quarter)
  • Year-over-year quarterly Capital expenditures decreased by -75.41%
  • Annual Capital expenditures for 2020 was $-1.04 Million (a 687.88% increase from previous year)
  • Twelve month Capital expenditures ending June 29, 2021 was $-521 Thousand (a -2.25% decrease compared to previous quarter)
  • Twelve month trailing Capital expenditures decreased by -49.02% year-over-year
Trailing Capital expenditures for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-521 Thousand $-533 Thousand $-1.04 Million $-1.02 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of Phathom Pharmaceuticals, Inc.

Most recent Capital expendituresof PHAT including historical data for past 10 years.

Interactive Chart of Capital expenditures of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.05 $-0.17
2020 $-0.12 $-0.18 $-0.06 $-0.68 $-1.04
2019 $-0.11 $-0.03 $-0.13
2018 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.